RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

That doesn't preclude COR providing enough detail to lay this to rest, without providing their competitors with proprietary information. Something along the lines of "the FDA was unconvinced by our explanation of histological anomalies as post-mortem artifact of the fixation process" vs "the FDA determined that CX-717 induced histological changes that could not be accounted for as artifacts of the fixation process".

In the former case, one could read: "we tried to convince them that there wasn't a problem, but they didn't buy it" vs "there really was a problem". Obviously, it would be better if it just boiled down to the FDA covering its ass, but I also feel that COR would benefit from a frank admission that there were problems with CX-717, because that would at least account for the decision, and thereby contain the damage (i.e., specific to CX-717).

Right now, I think the perception is that COR is a failing company with a tainted platform. The ADHD IND could not have gone worse, but the fallout perhaps could have been handled better.